Interest in quantitative imaging of Y-90 is growing because transarterial radioembolization (RE) with Y-90 loaded microspheres is a promising and minimally invasive treatment that is FDA approved for unresectable primary and metastatic liver tumors. These cancers are a leading cause of cancer mortality and morbidity. Radioembolization is a therapy that irradiates liver tumors with radioactive microspheres administered through
a microcatheter placed in the hepatic arterial vasculature. Radioembolization is based on the principle that healthy liver and tumor are mainly vascularized by the portal vein and the hepatic artery respectively. As a result, radioactive microspheres are preferentially located in the lesions after they are administered via the hepatic artery.
Internally administered targeted radionuclide therapy (TRT) with radio-labelled targeting molecules that deliver cytotoxic radiation to tumor has been used successfully to treat multiple cancers. Lu-177, used increasingly in TRT, emits both beta particles that deliver the therapeutic effect. FDA recently approved a fixed activity (4 cycles of 7.4 GBq/cycle as in NETTER -1) administered every 8 weeks. With the patient studies under this treatment, we collected CT images and corresponding volume of interest (organs, lesions) contours.